• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“如果你愿意,你可以隐藏它,如果你愿意,你也可以让它被看到”:一项使用 Omnipod DASH® 系统的澳大利亚 1 型糖尿病成人生活体验的定性研究。

"You can hide it if you want to, you can let it be seen if you want to": A qualitative study of the lived experiences of Australian adults with type 1 diabetes using the Omnipod DASH® system.

机构信息

Cairnmillar Institute, Camberwell, Victoria, Australia.

Cairnmillar Institute, Camberwell, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

出版信息

Diabetes Res Clin Pract. 2024 Feb;208:111123. doi: 10.1016/j.diabres.2024.111123. Epub 2024 Feb 2.

DOI:10.1016/j.diabres.2024.111123
PMID:38309532
Abstract

AIMS

Understanding the lived experience of using a tubeless insulin pump and how this differs compared to usual care (tubed insulin pump therapy (IPT) vs multiple daily injections (MDI)).

METHODS

Interviews were conducted after 12-weeks of using the Omnipod DASH Insulin Management System (Insulet, Acton, MA) and analysed using thematic analysis.

RESULTS

Fifty-eight adults (35 female; mean age 42;SD 13 years; 35 previous MDI) were interviewed. Most (84 %) wanted to continue using the device. Experiences fit two themes: 1. Taking back control of my diabetes: many previous MDI users perceived improved glycaemic control, explained by more "nuanced" control, with some reporting positive effects during exercise and sleep. Many previous MDI and IPT users endorsed positive experiences in concealing or disclosing their diabetes to others. However, some previous MDI users reported negative psychosocial experiences due to feeling continuously "attached" to their diabetes. 2. Barriers and facilitators of device acceptability: both MDI and IPT users cited wearability, alarms and the financial cost impacted their choice to continue device use. IPT users reported positive wearability experiences.

CONCLUSIONS

The tubeless pump improved diabetes management perceptions for both MDI and tubed pump users. However, participants' prior glucose management affected perceptions of its advantages and disadvantages.

摘要

目的

了解使用无管胰岛素泵的真实体验,以及与常规治疗(有管胰岛素泵治疗(IPT)与多次皮下注射(MDI))相比的不同之处。

方法

在使用 Omnipod DASH 胰岛素管理系统(Insulet,马萨诸塞州阿克顿) 12 周后进行了访谈,并采用主题分析进行分析。

结果

共访谈了 58 名成年人(女性 35 名;平均年龄 42 岁;SD 13 岁;35 名既往 MDI)。大多数(84%)受访者希望继续使用该设备。体验符合两个主题:1. 夺回对糖尿病的控制:许多既往 MDI 用户认为血糖控制得到改善,这可归因于更“细致”的控制,有些报告称在运动和睡眠期间有积极影响。许多既往 MDI 和 IPT 用户对向他人隐瞒或披露其糖尿病的经历表示认可。然而,一些既往 MDI 用户报告称由于感觉持续“依附”于其糖尿病,存在负性心理社会体验。2. 设备可接受性的障碍和促进因素:MDI 和 IPT 用户都提到了可穿戴性、警报和经济成本对他们继续使用设备的选择产生了影响。IPT 用户报告了积极的可穿戴体验。

结论

无管泵改善了 MDI 和有管泵使用者的糖尿病管理认知。然而,参与者既往的血糖管理影响了他们对其优缺点的看法。

相似文献

1
"You can hide it if you want to, you can let it be seen if you want to": A qualitative study of the lived experiences of Australian adults with type 1 diabetes using the Omnipod DASH® system.“如果你愿意,你可以隐藏它,如果你愿意,你也可以让它被看到”:一项使用 Omnipod DASH® 系统的澳大利亚 1 型糖尿病成人生活体验的定性研究。
Diabetes Res Clin Pract. 2024 Feb;208:111123. doi: 10.1016/j.diabres.2024.111123. Epub 2024 Feb 2.
2
Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.1 型糖尿病成人患者使用 Omnipod DASH 的治疗满意度:一项非盲 1:1 随机对照试验。
J Clin Endocrinol Metab. 2024 Jul 12;109(8):1984-1995. doi: 10.1210/clinem/dgae088.
3
A pilot randomised controlled parallel arm trial evaluating treatment satisfaction with the Omnipod DASH Insulin Management System compared with usual care in adults with type 1 diabetes in Australia: rationale, study design and methodologies.一项评估与澳大利亚1型糖尿病成人常规护理相比,使用Omnipod DASH胰岛素管理系统的治疗满意度的试点随机对照平行组试验:原理、研究设计和方法。
Pilot Feasibility Stud. 2023 Oct 9;9(1):171. doi: 10.1186/s40814-023-01400-4.
4
Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registry.长期研究显示,与多次每日注射相比,无管胰岛素泵治疗在青少年 1 型糖尿病患者中的效果:来自德国/奥地利 DPV 登记处的数据。
Pediatr Diabetes. 2018 Aug;19(5):979-984. doi: 10.1111/pedi.12658. Epub 2018 Apr 15.
5
A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.1型糖尿病灵活强化胰岛素治疗期间胰岛素泵治疗与多次注射的群组随机试验、成本效益分析及社会心理评估:REPOSE试验
Health Technol Assess. 2017 Apr;21(20):1-278. doi: 10.3310/hta21200.
6
Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision.接受基于碳水化合物计数教育和推注计算器的多次胰岛素皮下注射和胰岛素泵治疗的 1 型糖尿病患者的进餐时间血糖
Diabetes Res Clin Pract. 2021 Sep;179:109000. doi: 10.1016/j.diabres.2021.109000. Epub 2021 Aug 26.
7
Impact of the Omnipod Insulin Management System on Quality of Life: A Survey of Current Users.智凯胰岛素管理系统对生活质量的影响:对现有使用者的调查。
Diabetes Technol Ther. 2016 Oct;18(10):664-670. doi: 10.1089/dia.2016.0239. Epub 2016 Sep 27.
8
Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion.Omnipod胰岛素管理系统对既往接受多次每日注射或持续皮下胰岛素输注治疗的1型糖尿病患者血糖控制的疗效。
J Diabetes Sci Technol. 2016 Aug 22;10(5):1130-5. doi: 10.1177/1932296816638674. Print 2016 Sep.
9
Declining Frequency of Acute Complications Associated with Tubeless Insulin Pump Use: Data from 2,911 Patients in the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry.管饲胰岛素泵使用相关急性并发症的发生频率下降:来自德国/奥地利糖尿病患者病程记录登记处的 2911 例患者的数据。
Diabetes Technol Ther. 2021 Aug;23(8):527-536. doi: 10.1089/dia.2020.0675. Epub 2021 Jul 23.
10
Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.1 型糖尿病患者使用 Omnipod DASH 系统的真实世界结局:来自英国临床糖尿病学家协会 (ABCD) 研究的证据。
Diabetes Res Clin Pract. 2024 Mar;209:111597. doi: 10.1016/j.diabres.2024.111597. Epub 2024 Feb 27.